title: A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer.
authors.affiliation: Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20889, USA. walshej@mail.nih.gov
authors.forename: Janice M
authors.initials: JM
authors.lastname: Walshe
authors.forename: Neelima
authors.initials: N
authors.lastname: Denduluri
authors.forename: Arlene W
authors.initials: AW
authors.lastname: Berman
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Rosing
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Swain
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D009362:Neoplasm Metastasis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C485206:pertuzumab